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 ABBREVATIONS 
 
ALP - Alkaline Phosphatase 
PTH - Parathyroid Hormone 
Vit D - Vitamin D 
1,25(OH)2D3- 1,25,Hydroxyl Vitamin D 
AEDs - Anticonvulsant Drugs 
EEG - Electroencephalogram 
DBP - Vitamin D Binding Protein 
CKD - Chronic Kidney Disease 
INH - Isoniazid 
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GGT - Gamma Glutamyl Transpeptitase 
RANK - Receptor Activator Of NF-Kappa-B 
RANKL - Receptor Activator Of NF-Kappa-B Ligand 
M  - Meningitis 
PSS  - Post stroke seizure 
N  - Neurocysticercosis 
MR  - Mental Retardation 
TBM  - Tuberculous meningitis 
CPS  - Complex partial Seizure 
PTS  - Post traumatic seizure 
A  - Absense Seizure 
I  - Idiopathic seizure 
P  - Phenytoin 
S  - Sodium Valproate 
PB  - Phenobarbitone 
C - Carbamazepine 
Y  - Good seizure control 
N  - Poorseisure control 
  
 
 
 
 
 
 
 
INTRODUCTION 
INTRODUCTION 
Epilepsy is one of the well known disease entities causing 
significant morbidity. The staggering incidence and prevalence of 
5.35/1000(1) and 49.5/100,000(1) respectively in India, enhances its  
importance as a health issue which needs to be studied extensively. More 
so, since the treatment involves long term usage of drugs known to 
produce significant adverse effects. Hence, being in the era of evidence 
based and preventive medicine, it is the duty of the medical fraternity to 
evaluate the possibilities of preventing such adverse effects and reducing 
morbidity as much as feasible. 
It is well recognised that chronic anticonvulsant drug therapy 
produces significant disorders of bone and mineral metabolism.  In 
various anticonvulsant drug treated populations, the reported incidence of 
hypocalcemia, reduced serum 25-(OH) vitamin D concentration, elevated 
serum immunoreactive parathyroid hormone concentration, reduced bone 
mass, and histologic evidence of osteomalacia varies from 10-60%.(2)       
 Hence it becomes clear that epilepsy and the complications 
induced by its treatment are present in such high proportions in our 
community that it is difficult to be ignored. This study is an attempt at  
evaluating the presence of the above mentioned complications along with 
the possible pathophysiology supported by biochemical evidences. 
Current evidence indicates that anticonvulsant drugs induced 
alterations in the hepatic metabolism of vitamin D or its biologically 
active metabolites, plays an important role in the pathogenesis of this 
disease. The reduced 25- hydroxy vitamin D concentrations observed in 
this disorder are attributed variously to increased hepatic microsomal 
catabolism of vitamin D and 25 hydroxy vitamin D or to a direct 
inhibition of hepatic conversion of vitamin D to 25 hydroxy vitamin D. 
Investigations done in a large numbers of epileptic patients 
demonstrated that frank osteomalacia or rickets is relatively uncommon. 
By using photon absorption measurements, a moderate degree of bone 
demineralisation can be detected in most epileptic patients on chronic 
anticonvulsant drug treatment. 
The laboratory abnormalities most commonly seen are 
hypocalcemia, hypocalciuria, reduced 25 hydroxy vitamin D as well as 
elevated alkaline phosphatase and immunoreactive parathyroid hormone 
in serum(3). Based on clinical observation it appeared likely that the 
severity of the drug induced calcium and bone metabolism disorder 
depended on several factors like vitamin D intake, sun light  
 exposure, physical exercise, anticonvulsant dose, duration of therapy, and 
perhaps individual susceptibility. 
Hypocalcemia induced by anti convulsants, apart from causing 
bone abnormalities can also cause seizures per se.  Hypocalcemic 
seizures are uncommon and under diagnosed complication of long-term 
therapy with AEDs. Loss of seizure control in a patient stabilized on 
AEDs is an indication to check the patient's calcium status. Proper 
treatment of this complication is vitamin D and calcium supplementation. 
Prophylactic supplementation with vitamin D is necessary in 
institutionalized patients treated with AEDs.       
If the patient has pre-existing subclinical epilepsy, hypocalcemia 
may lower the excitation threshold for seizures. Electroencephalographic 
changes may be acute and nonspecific or present with distinct specific 
alterations. EEG changes may be present with or without symptoms of 
hypocalcemia. Some patients on anticonvulsive therapy have not needed 
medication after appropriate treatment of their hypocalcemia. The 
relationship between calcification of basal ganglia, cerebral cortex, or 
cerebellum with pre-existing epileptic or convulsive disorders is not well 
understood. In the elderly  
 population, disorientation or confusion may be manifestations of 
hypocalcemia. 
Hence, evaluation of these anti convulsant induced complications 
assumes importance in view of their treatable nature, which forms the 
rationale of my taking up this study.   
 
  
 
 
 
 
 
 
 
AIM  AND OBJECTIVES 
  
AIMS AND OBJECTIVES 
 
• To study the prevalence of calcium homeostasis abnormalities 
in patients on chronic anticonvulsant therapy. 
• To assess the serum  vitamin D level in patients on chronic 
anticonvulsant therapy. 
• To study the relationship between the seizure control and 
hypocalcemia. 
  
 
 
 
 
REVIEW OF  LITERATURE 
 REVIEW OF LITERATURE 
VITAMIN D 
Vitamin D is a fat soluble vitamin. It resembles sterols in structure 
and functions like a hormone. Vitamin D was isolated by August (1931) 
who named it calciferol. Vitamin D plays an essential role in 
calcium homeostasis and bone metabolism, induction of cell 
differentiation, inhibition of cell growth, immunomodulation, and control 
of other hormonal systems. 
Metabolism of Vitamin D 
Vitamin D is not a true vitamin, since nutritional supplementation 
is not required in humans who have adequate sun exposure. When the 
skin is exposed to ultraviolet radiation, the cutaneous precursor of 
vitamin D, 7-dehydrocholesterol, undergoes photochemical cleavage of 
the carbon bond between carbons 9 and 10 of the steroid ring. The 
resultant product, Previtamin D, is thermally labile and over a period of 
48 hours undergoes a temperature-dependent molecular rearrangement 
that results in the production of vitaminD(4) 
This thermally labile product can isomerize to two biologically 
inert products, luminosterol and tachysterol. This alternative 
photoisomerization prevents production of excessive amounts of vitamin 
D with prolonged sun exposure. The degree of skin pigmentation, which 
increases in response to solar exposure, also regulates the conversion of 
7-dehydrocholesterol to vitamin D by blocking the penetration of 
ultraviolet rays. 
Vitamin D is a hormone, not a vitamin-justification(46) 
1. Vitamin D is synthesized in the skin by ultra violet rays of sunlight. 
2. The biologically active form of vitamin D, calcitriol is produced in 
the kidney. 
3. Calcitriol acts on specific target organs-intestine, bone and kidney. 
4. Calcitriol action is similar to steroid hormones. It binds to a 
receptor in the cytosol and the complex acts on DNA to stimulate 
the synthesis of calcium binding protein. 
5. Calcitriol synthesis is self regulated by a feedback mechanism. 
Calcitriol decreases its own synthesis.  
Dietary sources of vitamin D(5)  
1. Fortified dairy products 
2. Egg yolks 
3. Fish oils 
4. Fortified cereal products. 
Recommended dietary allowance (RDA) 
The daily requirement of vitamin D is 400 international units or 10 
mg of cholecalciferol. In countries with good sunlight like India, the 
RDA for vitamin D is 200 IU or 5 mg of cholecalciferol. 
Vitamin D provided by plant sources is in the form of vitamin D2, 
whereas that provided by animal sources is in the form of vitamin D3. 
These two forms have equivalent biologic potencies and are activated 
equally efficiently by the hydroxylases in humans. 
Absorption of vitamin D  
Vitamin D is absorbed into the lymphatics and enters the 
circulation bound primarily to vitamin D binding protein, although a 
fraction of vitamin D circulates bound to albumin. The human vitamin D 
binding protein is an alpha2–globulin, with a molecular mass of  
approximately 52KD that is synthesized in the liver. The protein has a 
high affinity for 25(OH)D but also binds vitamin D and 1,25(OH)2 D. 
Approximately 88% of 25(OH)D circulates bound to the vitamin D 
binding protein, 0.03% is free, and the rest circulates bound to albumin.(6) 
In contrast, 85% of the circulating 1,25(OH)2 D3 binds to the vitamin D 
binding protein, 0.4% is free, and the rest binds to albumin.(7) Thus, the 
role of vitamin D binding protein is to maintain a serum reservoir and to 
modulate the activity of vitamin D metabolites. 
In the liver, vitamin D undergoes 25-hydroxylation by a 
cytochrome P450 like enzyme present in the mitochondria and 
microsomes. The half-life of 25(OH)D is approximately 2 to 3 weeks. 
The 25-hydroxylation of vitamin D is not tightly regulated. Therefore, the 
blood levels of 25(OH)D reflect the amount of vitamin D entering the 
circulation. When levels of vitamin D binding protein are low, such as in 
nephrotic syndrome, circulating levels of 25(OH)D are also reduced(8).  
The half-life of 25(OH)D is shortened by increases in levels of its 
active metabolite, 1,25(OH)2D3 .The final step in the production of the 
active hormone is the renal 1 -hydroxylation of 25(OH)D to 1,25(OH)2D3 
. The half-life of this hormone is approximately 6 to 8 hours.Like the 25-
hydroxylase,the1 -hydroxylase in the renal proximal convoluted tubule is 
a cytochrome P450 like mixed-function oxidase.(9,10,11) Unlike the 25-
hydroxylase, however, 1 -hydroxylase is tightly regulated. PTH and 
hypophosphatemia are the major inducers of this microsomal enzyme,(12) 
whereas calcium and the enzyme's product, 1,25(OH)2 D, repress it.  
Hormones such as estrogen, calcitonin, growth hormone, and 
prolactin increase 1 -hydroxylase activity. However, the clinical 
importance of these observations has not been established. Ketoconazole 
has been shown to decrease levels of 1,25(OH)2 D3 in a dose-dependent 
manner, presumably by interfering with 1 -hydroxylase activity.(16) 1 -
Hydroxylase is also found in keratinocytes,(11) the trophoblastic layer of 
the placenta,(14) some lymphomas,(15) and granulomata, including sarcoid 
granulomata.(16) 
In malignant and granulomatous tissue, the 1 -hydroxylase gene 
that is expressed is identical to that expressed in the kidney, but the gene 
is not regulated by PTH, phosphate, calcium, or vitamin D metabolites in 
these cells. Activation of macrophages with interferon, however, 
increases the expression of the 1-hydroxylase,(17) whereas treatment of 
sarcoidosis-associated hypercalcemia with glucocorticoids, 
ketoconazole,(18) or chloroquine(19) lowers serum 1,25(OH)2 D3 levels. 
The presence of 1 -hydroxylase in many target cells indicates 
autocrine and paracrine functions for 1,25(OH)2D3 in the control of cell 
proliferation and differentiation. This local production of 1,25(OH)2D3 is 
dependent on circulating precursor levels, providing a potential 
explanation for the association of vitamin D deficiency with various 
cancers  and autoimmune diseases. 
1,25(OH)2D3 Metabolism 
The high potency of 1,25(OH)2D3 in elevating serum calcium 
and phosphate levels requires a mechanism to attenuate its activity. This is 
accomplished within virtually all target cells by the 1,25(OH)2D3-
inducible vitamin D 24-hydroxylase, which catalyzes a series of oxidation 
reactions at carbons 24 and 23, leading to side chain cleavage and 
inactivation. 24-Hydroxylase is regulated in a reciprocal manner to 1 -
hydroxylase. Its activity and expression are increased by phosphate and 
reduced by PTH(20,21). The 24-hydroxylase gene contains at least 
two distinct vitamin D response elements that mediate the effects of 
1,25(OH)2D3 via its receptor on transcription(22,23). 
1,25(OH)2D3 can also be converted to the 1,25(R)-(OH)2D3- 
23(S),26-lactone. [24] This metabolite has mild antagonist activity toward 
1,25(OH)2D3 action(25) and more potent lactone analogues have now been 
developed. Recent studies have demonstrated that the 3 -hydroxyl group 
of 1,25(OH)2D3 can be epimerized to the 3  position(26,27) in a cell-specific  
manner. 1, 25(OH)2–3-epi-D3 appears to be catabolised more slowly than 
the parent hormone and retains significant biological activity.  
The significance of the 3-epimerase is not clear, but its cell-specific 
expression suggests that this pathway may function to prolong the activity 
of 1,25(OH)2D3 in cells containing this enzyme. Differential rates of 3-
epimerization of vitamin D analogues may provide a mechanism for their 
selective actions in vivo. In addition, evidence suggests that 3-
epimerization of select vitamin D analogues may enhance their 
proapoptotic activity. [28] 
Transport Of Vitamin D 
Vitamin D metabolites are lipophilic molecules with low aqueous  
solubility that must be transported in the circulation bound to plasma 
proteins. The most important of these carrier proteins is the vitamin D 
binding protein (DBP), which binds the metabolites with high affinity in 
the order 25(OH)D = 24,25(OH)2D > 1,25(OH)2D > vitamin D(29) . 
Plasma levels of DBP are 20 times higher than the total amount of 
vitamin D metabolites, and >99% of circulating vitamin D compounds are 
protein bound, mostly to DBP, although albumin and lipoproteins 
contribute to lesser degrees. This has a major impact on their 
pharmacokinetics. DBP-bound vitamin D metabolites have limited access 
to target cells(29) and, therefore, are less susceptible to hepatic metabolism 
 and subsequent biliary excretion, leading to a longer circulating half-life.  
Early evidence suggested that only the small fraction of unbound 
metabolites passively entered target cells to be further metabolized or to 
exert biological activity. For activated vitamin D compounds 
1,25(OH)2D3 and its analogues, biological activity was correlated with the 
concentration of free hormone . Thus DBP appears to buffer the free 
levels of active vitamin D compounds, guarding against vitamin D 
intoxication . 
DBP levels are not regulated by vitamin D but are reduced by liver 
disease, nephrotic syndrome, and malnutrition and increased during 
pregnancy and estrogen therapy. The concentration of free 1,25(OH)2D3, 
however, remains constant when DBP levels change, an example of the 
tight self-regulation of vitamin D metabolism. 
ACTIONS OF VITAMIN D 
Vitamin D Receptors 
1,25-Dihydroxyvitamin D3 exerts its biologic functions by binding 
to a nuclear receptor(30)  which regulates transcription of DNA into RNA. 
The vitamin D receptor most closely resembles the retinoic acid, 
triiodothyronine, and retinoid-X receptors. The affinity of the  receptor 
for 1,25(OH)2D3 is approximately three times higher than that for other 
vitamin D metabolites. Although 25(OH)D3 is less potent on a molar 
basis, its concentration in the serum is approximately three times higher 
than that of 1,25(OH)2 D3. However its free concentration is only twice 
that of 1,25(OH)2D3. Therefore, under normal circumstances it is unlikely 
that 25(OH)D3 contributes importantly to calcium homeostasis.  
Because the affinity of the vitamin D binding protein for 25(OH)D 
is greater than for 1,25(OH)2 D3 , in states of vitamin D intoxication, the 
free levels of 1,25(OH)2 D3 increase (31) because 25(OH)D displaces it 
from the vitamin D binding protein. 25-OH D, therefore, may play a role 
in the clinical syndrome of vitamin D intoxication both by its direct 
biologic effects, when present at toxic levels, and by increasing free 
levels of 1,25(OH)2 D3 . 
Role of vitamin D on Intestinal Calcium Absorption 
Under normal dietary conditions, calcium intake is in the range of 
700 to 900 mg daily. Approximately 30% to 35% of this calcium is 
absorbed.(32) Absorption of calcium is impaired by bile salt deficiency, 
unabsorbed free fatty acids in steatorrheic states, and high dietary content 
of fibre or phytate. Gastric acid is needed to promote dissociation of 
calcium from anionic components of food or therapeutic preparations of 
calcium salts. Administration of calcium salts with meals, especially in 
patients with achlorhydria, and use of divided doses or more soluble salts, 
such as calcium citrate, are commonly employed strategies to increase 
calcium bioavailability. 
Calcium is thought to be absorbed by three pathways:  
1. Transcellular route,  
2. Vesicular calcium transport, and  
3. Paracellular transport.  
The first pathway is dependent on 1,25(OH)2D3 . Although the 
necessity of vitamin D for paracellular and vesicular calcium absorption 
remains controversial, substantial evidence exists that the hormone 
enhances this pathway as well(33,34). 
Transcellular route 
 This pathway is thought to involve three steps: 
1. Entry of calcium into the enterocyte, 
2. Transport across the cell, and  
3. Extrusion across the basolateral membrane. 
Entry into the Enterocyte 
A number of brush border proteins, including the intestinal 
membrane calcium-binding protein, brush border alkaline phosphatase, 
and low-affinity Ca2+ -Mg2+ -ATPase, are induced by 1,25(OH)2 D3. 
The activity of these proteins correlates with active calcium transport(35) 
.Two calcium channels, CaT1(36) and EcaC,(37) with six membrane-
spanning domains are expressed in the duodenum and jejunum and have 
been implicated as important regulators of calcium entry into the 
enterocyte. Upon entering the enterocyte, calcium binds to components of 
the brush border complex subjacent to the plasma membrane. Calmodulin 
is redistributed to the brush border in response to 1,25(OH)2 D3  
Transport across cell 
The best-studied effect of vitamin D on the enterocyte is the 
induction of synthesis of the intestinal calcium-binding protein calbindin 
9K. This protein has an EF hand structure that permits the binding of two 
calcium ions per molecule. The affinity of calbindin for calcium is 
approximately four times that of the brush border calcium-binding 
components. Thus, calcium is preferentially transferred to calbindin. 
Calbindin serves to buffer the intracellular free calcium concentration 
during calcium absorption. It associates with microtubules and may play 
a role in the transport of calcium across the enterocyte. Organelles such 
as the mitochondria, Golgi, and endoplasmic reticulum also serve as 
repositories for intracellular calcium. 
Exit from the Enterocyte 
The transport of calcium across the antiluminal surface of the 
enterocyte, the final process involved in intestinal calcium absorption, is 
dependent on 1,25(OH)2 D3. The main mechanism of calcium extrusion is 
the 1,25(OH)2 D3 –inducible ATP-dependent Ca2+ pump. The affinity of 
the pump for calcium is approximately 2.5 times that of calbindin(38). 
With high calcium intake, a 1,25(OH)2 D3 -independent Na+ -Ca2+ 
exchanger may play a role in the transfer of calcium across the basolateral 
membrane as well. 
Vitamin D-Actions on Bone 
1,25-Dihydroxyvitamin D3 is a major transcriptional regulator of 
the two most abundant bone matrix proteins. It represses the synthesis of 
type I collagen(39) and induces the synthesis of osteocalcin(40). 1,25-
dihydroxyvitamin D3 promotes the differentiation of osteoclasts from 
monocyte-macrophage stem cell precursors in vitro, and it also increases 
osteoclastic bone resorption in high doses in vivo, by stimulating 
production of osteoclast-differentiating factor by osteoblasts.(41) 
Vitamin D-Actions on kidney 
Calcitriol is also involved in minimizing the excretion of calcium 
and phosphate through the kidneys, by decreasing their excretion and 
enhancing reabsorption. All these effects ultimately lead to increase in 
plasma calcium level. 
Vitamin D-Action on muscle 
One of the striking clinical features of profound vitamin D 
deficiency that remains unexplained is the severe proximal myopathy (42). 
Muscle cells express vitamin D receptors, and 1,25(OH)2 D3 has 
nongenomic effects on muscle(43). Furthermore, 1,25(OH)2D3 increases 
amino acid uptake and alters phospholipid metabolism in vitro in muscle 
cells(42). 
Vitamin D administration has been shown to increase the 
concentration of troponin C, a calcium-binding protein that plays a role in 
excitation coupling and increases the rate of uptake of calcium by the 
sarcoplasmic reticulum(43). 
Vitamin D deficiency causes(45) 
• Malabsorption, Dietetary deficiency, Iimpaired cutaneous 
production. 
• Accelerated loss-Impaired enterohepatic circulation, Increased 
metabolism (Barbiturates, Phenytoin, Rifampin). 
• Impaired 25 hydroxylation-Liver diseases, Isoniazid. 
• Impaired 1 alpha hydroxylation-CKD, Hypoparathyroidism,  
1-alpha hydroxylase mutation, Oncogenic osteomalacia, x-linked 
hypophosphatemic rickets. 
• Target organ resistance -Phenytoin, vitamin D receptor mutation. 
• Drugs-Phenytoin, INH, Barbiturates, Ketoconazole.      
Vitamin D deficiency-Clinical features(46) 
• RICKETS 
Rickets is derived from an old English word wrick ken, meaning to 
twist. In childrens vitamin D deficiency results in growth retardation 
associated with an expansion of the growth plate. There will be expansion 
of the hypertrophic chondrocyte layer. It is characterized by bone 
deformities, resulting soft and pliable bones and delay in teeth formation. 
The weight-bearing  bones are bent to form bow-legs. 
• OSTEOMALACIA 
Osteomalacia is derived from greek (osteon-bone; malakia-
softness). There is  impaired mineralization of bone matrix proteins , 
increasing their susceptibility to fracture. 
 
 
• PROXIMAL MYOPATHY 
  The myopathy that accompanies vitamin D deficiency is 
characterized by normal creatine kinase levels, a myopathic 
electromyogram, and biopsy findings of loss of myofibrils, fatty 
infiltration, and interstitial fibrosis. The myopathy resolves within days to 
weeks of vitamin D replacement and is not related to normalization of 
mineral ion homeostasis. 
Vitamin D deficiency – Laboratory Diagnosis(45) 
 1) Serum 25(OH)D level 
    - optimal level in serum >25 ng/ml 
    - in vitamin D deficiency, it will be less than 15 ng/ml 
    - paradoxically 1,25(OH)2 D are often normal in severe vitamin D      
deficiency. Since, PTH is major stimuli for 1 alpha hydroxylase, 
there is increased level of  1,25(OH)2D 
2) Low serum calcium level 
3) Low serum phosphorus level 
4) Elevated serum alkaline phosphatase level 
5) Radiography 
   - widended , expanded growth plate 
   - swelling of costochondral junction, rachitic rosary 
   - decrease in cortical thickness and relative radiolucency of skeleton 
 - Pseudofracture or looser’s zones   
    Radiolucent lines that occurs in areas of contact with the  
    underlying skeletal element 
Vitamin D deficiency-Treatment(45) 
- Vitamin D supplementation 
50,000 IU weekly for 3-12 weeks followed by 800 IU daily as 
maintenance dose 
- Calcium supplementation 
  1.5 to 2 g/day of elemental calcium 
- Normocalcemia is observed within one week of therapy 
- Elevated ALP and PTH may persist for 6 month 
          
CALCIUM  HOMEOSTASIS 
Ca2+ is a universal intracellular messenger that participates in 
numerous biological processes from neural regulation to 
muscle contraction, and from gene expression to cell growth and death. It 
is the most abundant among the minerals in the body. It is therefore no 
surprise there that a variety of mechanisms exist to ensure that plasma 
calcium concentrations are kept within a relatively narrow band. 
In an average adult human, there is over 1 kg of calcium within the 
body. Most of this is present within the skeleton, where the vast majority 
is in the form of relatively insoluble calcium hydroxyapatite, although 
there is some more soluble complexed calcium. Further 0.6% of body’s 
calcium is found within teeth, with a similar amount being found in the 
soft tissues and a much smaller quantity being present within the body 
fluids. 
In plasma, calcium exists in three forms. The most important of 
these comprising approximately 50% of the total calcium, is its ionized 
form. This calcium is fully available for use within biological systems. 
This fraction of calcium is subject to physiological control. Further 5% of 
calcium is loosely complexed to anions such as citrate or phosphates. In 
this form calcium is not directly available for biological processes but can 
rapidly dissociate from the anions and become available. Third, plasma 
calcium (45%) is bound to plasma proteins, particularly albumin. 
 
 
Biochemical functions of calcium(46) 
1) Development of bones and teeth 
2) Muscle contraction 
Calcium interacts with troponin c to trigger muscle contraction, 
also increases interaction between actin and myosin 
3) Blood coagulation 
Calcium acts as factor 4 in coagulation pathway 
4) Nerve transmission 
5) Membrane integrity and permeability 
Calcium influences the membrane structure and transport of water 
and several ions. 
6) Activation of enzymes 
Calcium is needed for the direct activation of enzymes such as 
lipase, ATPase and succinate dehydrogenase. 
7) Calmodulin mediated action of calcium 
Calcium-calmodulin complex activates certain enzymes like, 
adenylate cyclise, calcium dependent protein kinases. 
8) Calcium is an intracellular messenger 
Calcium is regarded as a second messenger for some hormonal 
action like for epinephrine in liver glycogenolysis , and for ADH 
action on kidney. 
9) Release of hormones 
                  Insulin, PTH,  calcitonin release is facilitated by calcium 
10) Secretory process 
11) Role in cell-to-cell communication 
12) Acts on myocardium and prolongs systole  
Calcium- Normal ranges(46) 
The serum level of calcium is closely regulated with a normal total 
calcium of 2.2-2.6 mmol/L (9-10.5 mg/dL) and a normal ionized 
calcium of 1.1-1.4 mmol/L (4.5-5.6 mg/dL). The amount of total calcium 
varies with the level of serum albumin, a protein to which calcium is 
bound. The biologic effect of calcium is determined by the amount 
of ionized calcium, rather than the total calcium. Ionized calcium does not 
vary with the albumin level, and therefore it is useful to measure the 
ionized calcium level when the serum albumin is not within normal 
ranges. 
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One can derive a corrected calcium level when the albumin is 
abnormal. This is to make up for the change in total calcium due to the 
change in albumin-bound calcium, and gives an estimate of what the 
calcium level would be if the albumin were within normal ranges. 
 
Corrected calcium (mg/dL) = Measured total Ca (mg/dL) +  
                                              0.8 (4.0 - Serum albumin [g/dL]), 
4.0 represents the average albumin level in g/dL. 
 
Every 1 g/dL decrease of albumin will decrease 0.8 mg/dL in 
measured serum calcium and thus 0.8 must be added to the measured 
calcium to get a corrected calcium value. 
Sources of calcium 
• Milk 
• Egg 
• Fish 
• Vegetables 
• Wheat  
• Rice 
Factors necessary for Absorption 
1. Calcium absorption is increased by the following: 
         a. Vitamin D 
         b. Parathyroid hormone 
         c. Acidity 
         d. Aminoacids 
2. Calcium absorption is decreased by the following: 
         a. Phytic acid in cereals 
         b. Oxalates in leafy vegetables 
         c. Malabsorption syndrome 
         d. High phosphate content 
Low Plasma Calcium: Stimulates PTH release, and PTH acts to 
reabsorb Ca2+ from the pool in bone and to enhance renal re-absorption of 
Ca2+ 
High Plasma Calcium: Stimulates calcitonin CT secretion which 
lowers plasma calcium by inhibiting bone resorption. 
HYPOCALCEMIA(serum calcium level<8.5 mg/dl)(46) 
Hypocalcemia can present as an asymptomatic laboratory finding 
or as a severe, life-threatening condition .In the setting of acute 
hypocalcemia, rapid treatment may be necessary. In contrast, chronic 
hypocalcemia may be well tolerated, but treatment is necessary to prevent 
long-term complications.  
HYPOCALCEMIA-CLINICAL FEATURES(63) 
Signs and symptoms  due to Neuromuscular irritability 
• Chvostek's sign 
• Trousseau's sign 
• Paresthesias 
• Tetany 
• Seizures (focal, petit mal, grand mal) 
• Fatigue 
• Anxiety 
• Muscle cramps 
• Polymyositis 
• Laryngeal spasms, Bronchial spasms 
 
Other Neurological signs 
• Extrapyramidal signs due to calcification of basal ganglia 
• Calcification of cerebral cortex or cerebellum 
• Personality disturbances 
• Irritability 
• Impaired intellectual ability 
• Nonspecific EEG changes 
• Increased intracranial pressure 
• Parkinsonism 
• Choreoathetosis 
 
Ectodermal changes 
 
• Dry skin 
• Coarse hair 
• Brittle nails 
• Alopecia 
• Enamel hypoplasia 
• Shortened premolar roots 
• Thickened lamina dura 
• Delayed tooth eruption 
• Increased dental caries 
• Atopic eczema 
• Exfoliative dermatitis 
 
Smooth muscle involvement 
 
• Dysphagia 
• Abdominal pain 
• Biliary colic 
• Dyspnea 
 
 
Ophthalmologic manifestations 
• Subcapsular cataracts  
• Papilledema 
Cardiac manifestations 
• Prolonged QT interval in ECG 
• Congestive heart failure and cardiomyopathy 
The hallmark of acute hypocalcemia is neuromuscular irritability. 
Clinically, neuromuscular irritability can be demonstrated by eliciting 
Chvostek's or Trousseau's signs.  
Chvostek's sign (Weiss sign) 
It was first described by Frantichek chvostek in 1876(48) 
CAUSES: 
1. Hypocalcemia 
2. Hypomagnesemia 
3. Respiratory alkalosis , particularly following hyperventilation  
Tapping the skin over the facial nerve anterior to the external 
auditory meatus produces this sign. Ipsilateral contraction of the facial 
muscles occur due to hyperexcitability of facial nerve. 
Trousseau's sign 
Trousseau’s sign is thought to be both sensitive and specific for 
hypocalcemic tetany(49,50). This sign is induced by inflation of a blood 
pressure cuff to 20 mm Hg above the patient's systolic blood pressure for 
3-5 minutes. Carpal spasm presents as flexion of the wrist in metacarpo 
phalangeal joints, extension of the interphalangeal joints, and abduction 
of the thumb. 
ANTICONVULSANTS AND CALCIUM HOMEOSTASIS(52,53,54,55)  
Chronic usage of anticonvulsant therapy may interfere with 
calcium homeostasis in many ways as follows, 
1)  They can accelerate hepatic inactivation of vitamin D(56,57) 
The anticonvulsant therapy is associated with induction of hepatic 
microsomal system resulting in increased catabolism and excretion of 
vitamin D and depletion of biologically active vitamin D metabolites in 
the body. In view of this observations one would expect that the 
decreased availability of 25(OH)D substrate would cause a deficiency of 
the active metabolite1, 25(OH)2D leading to rickets and osteomalacia. 
2) They can cause target organ resistance to vitamin D action(58,59) 
3) They can directly reduces the calcium absorption from GIT(56,57) 
Anticonvulsants may inhibit gastrointestinal calcium  absorption  
and  bone  formation  through  end-organ hypo responsiveness  to  
1,25(OH)2D  and by reduced  tissue concentration  of active  vitamin  D 
metabolites 
4) They impair PTH/1, 25(OH)2D3 mediated bone resorption(60) 
5)  Inhibition of calcitonin secretion(60). 
6)  Inhibition  of Calcium and phosphorus  Excretion(61) 
Antiepileptic  drugs  may  provoke  renal  conservation  of calcium  
and  phosphate  and  possibly  compensate  partly the  above mentioned  
negative  effects on  calcium and  bone metabolism.  This  may  explain  
the  relatively  low  incidence  of manifest  rickets  or  osteomalacia  
despite  long-term  treatment with  drugs  that  are  now well known  to  
interfere with  so many important  factors  of calcium  homeostasis.  
Because of this hypocalcemia, the parathyroid glands are 
stimulated to produce PTH  to maintain the serum calcium level. The 
parathormone tries to maintain the serum calcium level by its action on 
kidney, bone, and vitamin D mediated increased calcium absorption from 
GIT. Due to the PTH – induced increase in bone turn over, alkaline 
phosphatase levels are often elevated. Phenytoin(53), Phenobarbitone, 
Sodium Valproate, and Carbamazepine have been proven to cause 
disturbances in calcium homeostasis through one or more of the above 
mentioned mechanisms.(53,54,55) 
SEIZURE CONTROL AND HYPOCALCEMIA(51) 
If the patient has pre-existing subclinical epilepsy, hypocalcemia 
may lower the excitation threshold for seizures. Electroencephalographic 
changes may be acute and nonspecific or present with distinct changes in 
the electroencephalogram (EEG). EEG changes may be present with or 
without symptoms of hypocalcemia. Some patients on anticonvulsive 
therapy have not needed medication after appropriate treatment of their 
hypocalcemia. The relationship between calcification of basal ganglion, 
cerebral cortex, or cerebellum with pre-existing epileptic or convulsive 
disorders is not well understood. In the elderly population, disorientation 
or confusion may be manifestations of hypocalcemia. 
ALKALINE PHOSPHATASE (ALP) 
ALP is a hydrolase enzyme responsible for removing 
phosphate groups from many types of molecules, nucleotides, proteins, 
and alkaloids. The process of removing the phosphate group is 
called dephosphorylation. As the name suggests, alkaline phosphatases 
are most effective in an alkaline environment. It is sometimes used 
synonymously as basic phosphatase(52). 
In humans, alkaline phosphatase is present in all tissues throughout 
the entire body, but is particularly concentrated in liver, bile 
duct, kidney, bone, and the placenta. 
The normal range is 20 to 180 IU/L.[63]  Levels are significantly 
higher in children and pregnant women. Also, elevated ALP indicates that 
there could be active bone formation occurring as ALP is a by product 
of osteoblast activity. 
When ALP is elevated, isoenzyme  studies using 
electrophoresis can confirm the source of the ALP. Heat stability also 
distinguishes bone and liver isoenzymes. 
Causes For Elevated Alkaline Phosphatase 
Liver ALP 
 Cholestasis, 
  Cholecystitis, 
  Cholangitis, 
  Cirrhosis, hepatitis, fatty liver, 
  Sarcoidosis,  
 Liver tumor,  
	 Liver metastasis 

 Drugs intoxication 
Concurrently elevated GGT (gamma glutamyl transpeptitase) helps 
rule in favour of liver metastasis (rather than bone, kidney) when 
assessing spread of cancer. 
Bone/skeletal causes 
Bone diseases 
1) Paget’s disease, Osteosarcoma ,Secondaries 
2) Renal osteodystrophy 
3) Multiple myeloma 
4) Bone fracture 
Skeletal involvement of other primary diseases 
1) Vitamin D deficiency   
2) Osteomalacia   
3) Rickets 
4) Secondary hyperparathyroidism 
 Other causes 
1) Polycythemia vera 
2) Myelofibrosis 
3) Leukemoid reaction due to infection 
4) Pregnancy 
5) Women using hormonal contraception 
 
PARATHYROID HORMONE (PTH) 
 Parathormone or parathyrin, is secreted by the parathyroid glands as 
a polypeptide containing 84 amino acids. PTH acts to increase the 
concentration of calcium in the blood by acting upon parathyroid 
receptors in three parts of the body. PTH half-life is approximately 4 
minutes.(64) It has a molecular mass of 9.4 KDa.[65]  
PTH-Action on bone 
It enhances the release of calcium from the large reservoir contained 
in the bones.[66] Bone resorption is the normal destruction of bone 
by osteoclasts, which are indirectly stimulated by PTH. Stimulation is 
indirect, since osteoclasts do not have a receptor for PTH. PTH binds 
to osteoblasts, the cells responsible for creating bone. Binding stimulates 
osteoblasts to increase their expression of RANKL and inhibits their 
expression of  osteoprotegrin. It binds to RANKL and blocks it from 
interacting with RANK, a receptor for RANKL. The binding of RANKL 
to RANK stimulates these osteoclast precursors to fuse, forming new 
osteoclasts which ultimately enhance bone resorption. 
 
PTH-Action on kidney 
It enhances active reabsorption of calcium and magnesium 
from distal tubules and the thick ascending limb. As bone is degraded 
both calcium and phosphate are released. It also greatly increases the 
excretion of phosphate, with a net loss in plasma phosphate 
concentration. It thus increases the calcium:phosphate ratio  and more 
calcium is free in circulation. 
PTH-Action on Gut 
It enhances the absorption of calcium in the intestine by increasing 
the production of activated vitamin D. Vitamin D activation occurs in the 
kidney. PTH up-regulates 25-hydroxyvitamin D3 1-alpha-hydroxylase, the 
enzyme responsible for 1-alpha hydroxylation of 25 hydroxy vitamin D, 
converting vitamin D to its active form (1,25-dihydroxy vitamin D). This 
activated form of vitamin D increases the absorption of calcium (as 
Ca2+ ions) by the intestine via calbindin. 
 
Regulation of PTH secretion 
Secretion of parathyroid hormone is controlled chiefly 
by serum [Ca2+] through negative feedback. Calcium sensing receptors 
located on parathyroid cells, are activated when [Ca2+] is low[67] .  In the 
parathyroid gland, sensation of high concentrations of extracellular 
calcium result in activation of the Gq G-protein coupled cascade through 
the action of phospholipase C. This hydrolyzes phosphatidylinositol 4,5-
bisphosphae (PIP2) to liberate intracellular messengers IP3 and 
diacylglycerol (DAG). Ultimately, these two messengers result in a 
release of calcium from intracellular stores and a subsequent flux of 
extracellular calcium into the cytoplasmic space. The effect of this 
signaling of high extracellular calcium results in an intracellular calcium 
concentration which inhibits the secretion of preformed PTH from 
storage granules in the parathyroid gland. 
Stimulators of PTH 
1) Decreased serum [Ca2+]. 
2) Mild decreases in serum [Mg2+]. 
3) An increase in serum phosphate 
Since increased phosphate will complex with serum calcium to 
form calcium phosphate, which causes the Ca-sensitive receptors (CaSR) 
to think that serum Ca has decreased, as CaSR do not sense Calcium 
phosphate, thereby triggering an increase in PTH. 
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1) Increased serum [Ca2+] 
2) Severe decreases in serum [Mg2+], which also produces symptoms of  
hypoparathyroidism. 
Measurement 
PTH can be measured in the blood in several different forms intact 
PTH N-terminal PTH, mid-molecule PTH, and C-terminal PTH, and 
different tests are used in different clinical situations. The average PTH 
level is 10-80 pg/ml(42). 
  
 
 
 
 
MATERIALS  AND METHODS 
 MATERIALS AND METHODS 
STUDY DESIGN 
 Cross sectional single centred prevalence study 
STUDY CENTRE 
 Government General Hospital, Chennai 
  Period   of the study   :        May 2010 to October 2010 
  Ethical clearance        :        Granted 
  Consent                       :        Informed consent from all patients. 
INCLUSION CRITERIA 
1) Patients attending the epilepsy clinic who are on the following  single 
or   multiple  anti- convulsants  commonly used in our hospital, 
• Phenytoin 
• Phenobarbitone 
• Sodium valproate 
• Carbamazepine          
2) Patients taking the above mentioned drugs for more than 6 months  
3) Any patient with seizure disorder was considered, irrespective of 
whether the seizures were primary or secondary 
        
EXCLUSION CRITERIA 
1) Patients with chronic kidney disease 
2) Patients with chronic liver disease 
3) Malabsorption syndromes  
The above mentioned conditions may per se cause disturbances in 
calcium homeostasis and hence were excluded from the study. 
4) Patients on any other drug that may interfere with calcium 
homeostasis 
        5) Non compliance with anti convulsant therapy 
ANALYSIS 
Data analyzed using statistical package - SPSS Software. 
CONFLICT OF INTEREST -   Nil. 
EXTERNAL FINANCIAL SUPPORT – Nil 
 
METHODOLOGY 
• 100 patients with seizure disorder attending the GGH, Chennai, 
were randomly selected for the study, after applying the inclusion 
and exclusion criteria. 
• Detailed history regarding epilepsy treatment, compliance and 
seizure control was taken from all the patients enrolled for the 
study.  
• The data regarding the number and duration of anti convulsant 
usage was collected  
• Complete physical examination was carried out on all the patients. 
• Serum calcium, vitamin D, Alkaline phosphatase and 
Parathormone  levels were measured. 
• Calcium levels were corrected in cases with hypoalbuminemia. 
• Renal and Liver function tests were done to rule out other 
important causes of  hypovitaminosis D. 
• The results were analysed using SPSS software statistical pack. 
  
 
 
 
 
 
RESULTS AND OBSERVATION 
 RESULTS AND OBSERVATION 
TABLE - 1 
Prevalence of hypocalcemia in patients on chronic Anticonvulsant 
Therapy 
Calcium level No of patients Percentage 
Hypocalcemia 32 32% 
Normocalcemia 68 68% 
Total 100 100% 
 
 
 
The prevalence of hypocalcemia in patients taking anticonvulsants 
for a long time (>6 months) is 32%. 
TABLE - 2 
Age distribution and hypocalcemia 
Age 
Group in 
years 
 Normocalcemia Hypocalcemia Total 
P 
value 
Number 20 10 30 
Below 20 
percentage 66.7% 33.3% 100.0% 
Number 19 8 27 
21-30 
percentage 70.4% 29.6% 100.0% 
Number 21 12 33 
31-40 
percentage 63.6% 36.4% 100.0% 
Number 8 2 10 
Above 40 
percentage 80.0% 20.0% 100.0% 
Number 68 32 100 
Total 
percentage 68.0% 32.0% 100.0% 
>0.005 
   
 
There is no significant correlation between age and incidence of 
hypocalcemia in patients taking chronic anticonvulsant therapy 
TABLE - 3 
Sex distribution and hypocalcemia 
Gender  Hypocalcemia Normocalcemia Total Significance 
Count 18 32 
Males 
Percentage 36.0% 64.0% 
50 
Count 14 36 
Females 
percentage 28.0% 72.0% 
50 
count 32 68 
Total 
percentage 32.0% 68.0% 
100 
>0.005 
 
 
 
 
 
 
 
There is no significant association between the age distribution 
and incidence of hypocalcemia in patients on chronic anticonvulsant 
therapy. 
TABLE - 4 
Number of drugs and calcium level 
No. of 
Drugs  Normocalcemia Hypocalcemia Total 
P  
value 
Number 56 9 65 
1 
percentage 86.2% 13.8% 100.0% 
Number 10 17 27 
2 
percentage 37.0% 63.0% 100.0% 
Number 2 6 8 
3 
percentage 25.0% 75.0% 100.0% 
Number 68 32 100 
Total 
percentage 68.0% 32.0% 100.0% 
<0.001 
 
 
The prevalence of hypocalcemia is higher in patients using 
more number of anticonvulsant drugs. 
TABLE  - 5 
Duration of treatment and calcium level 
Duration  Hypocalcemia Normocalcemia Total P 
value 
Number 6 46 Upto 12 
months Percentage 11.5% 88.5% 
52 
Number 26 22 More 
than 12 
months Percentage 54.2% 45.8% 
48 
Number 32 68 
Total 
Percentage 32.0% 68.0% 
100 
<0.001 
 
 
In  patients taking anticonvulsants for more than a year, the 
chance of developing hypocalcemia is higher when compared to 
patients on drug treatment for less than a year. 
TABLE  -6 
Correlation between hypocalcemia and low vitamin D 
 
 
Presence of hypocalcemia was associated with low serum levels of 
vitamin D in a significant number of patients 
Vitamin 
D 
 Low 
calcium 
Normal 
calcium 
Total P value 
Count 21 2 Low Vit 
D 
Percentage 91.3% 8.7% 
23 
Count 11 66 Normal  
Vit D Percentage 14.3% 85.7% 
77 
Count 32 68 Total 
percentage 32.0% 68.0% 
100 
<0.001 
TABLE - 7 
Correlation between hypocalcemia and elevated PTH 
PTH 
Level  Hypocalcemia Normocalcemia Total P value 
Number 16 0 Elevated 
PTH Percentage 100% 0% 
16 
Number 16 68 Normal 
PTH Percentage 20.5% 80.9% 
84 
Number 32 68 
Total 
percentage 32.0% 68.0% 
100 
<0.001 
 
 
50% of hypocalcemic patients had secondary hyperparathyroidism. 
 TABLE - 8  
Seizure control and calcium level 
Seizure 
control 
 Hypocalcemia Normocalcemia Total P value 
Number 19 61 
Good 
Percentage 23.8% 76.3% 
80 
Number 13 7 
Poor 
Percentage 65.0% 35% 
20 
Number 32 68 
Total 
Percentage 32.0% 68.0% 
100 
< 0.001 
 
 
Hypocalcemia is associated with a higher incidence of poor 
seizure control . 
TABLE - 9 
Prevalence of abnormality in ALP in patients on chronic 
anticonvulsant therapy 
ALP level No of patients Percentage 
High ALP 25 25% 
Normal ALP 75 75% 
Total 100 100% 
 
 
 
The prevalence of elevated alkaline phosphotase in patients 
taking anticonvulsants for a long time (>6 months) is 25%. 
TABLE  - 10 
Age distribution and  elevated ALP 
Age  High ALP 
Normal 
ALP Total P value 
Number 9 21 
<20 
Percentage 30.0% 70.0% 
30 
Number 6 21 
20 to 30 
Percentage 22.2% 77.8% 
27 
Number 8 25 
30 to 40 
Percentage 24.2% 75.8% 
33 
Number 2 8 
>40 
Percentage 20.0% 80.0% 
10 
Number 25 75 
Total 
Percentage 25.0% 75.0% 
100 
>0.005 
 
 
There is no significant relation  between age distribution of the 
study population and the incidence of elevated ALP. 
 
TABLE - 11 
Sex distribution and elevated ALP 
SEX  High ALP 
Normal 
ALP Total P value 
Number 10 40 Male 
percentage 20.0% 80.0% 
50 
Number 15 35 Female 
percentage 30.0% 70.0% 
50 
Number 25 75 Total 
percentage 25.0% 75.0% 
100 
>0.005 
 
 
 
No difference in incidence of elevated ALP was found between 
both the sexes 
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TABLE - 12 
Number of anticonvulsants and elevated ALP 
 
No of 
anticonvulsants 
 High 
ALP 
Normal 
ALP Total P value 
Number 10 55 
1 
Percentage 15.4% 84.6% 
65 
Number 10 17 
2 
Percentage 37.0% 63.0% 
27 
Number 5 3 
3 
percentage 62.5% 37.5% 
8 
Number 25 75 
Total 
percentage 25.0% 75.0% 
100 
<0.001 
 
 
With increasing number of anti convulsants, there is an increased 
prevalence of elevaled ALP.  
TABLE - 13 
Duration of treatment and high ALP 
Duration 
of 
treatment 
 High 
ALP 
Normal 
ALP Total P value 
Number 8 44 Upto 12 
months Percentage 15.4% 84.6% 
52 
Number 17 31 Above 12 
months Percentage 35.4% 64.6% 
48 
Number 25 75 
Total 
percentage 25.0% 75.0% 
100 
<0.001 
 
 
The longer the anti convulsant usage, higher is the chance of 
elevated ALP. 
TABLE - 14 
Relationship of hypocalcemia and high ALP 
Calcium level  Normal ALP 
High 
ALP Total P value 
Number 62 6 
Normocalcemia 
Percentage 91.2% 8.8% 
68 
Number 13 19 
Hypocalcemia 
Percentage 40.7% 59.3% 
32 
Number 75 25 
Total 
Percentage 75.0% 25.0% 
100 
<0.005 
 
 
Hypocalcemia correlated with elevated ALP and normocalcemia 
with normal ALP levels. 
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TABLE -15 
Correlation between vitamin D and PTH level 
PTH 
level 
 Low 
Vit D 
Normal 
Vit D 
Total P value 
Number 14 2 Elevated  
PTH Percentage 87.5% 12.5% 
16 
Number 9 75 Normal   
PTH Percentage 10.8% 89.2% 
84 
Number 23 77 
Total 
percentage 23.0% 77.0% 
100 
<0.001 
 
 
A significant number of patients with low vitamin D values also 
had elevated PTH levels. 
TABLE  -16 
Correlation of serum phosphorus and number of anticonvulsants 
Number 
of drugs 
 Hypophosphatemia Normal PO4+ 
Total P Value 
Number 9 56 65 
1 
Percentage 13.8% 86.2% 100% 
Number 16 11 27 
2 
Percentage 59.3% 40.7% 100% 
Number 6 2 8 
3 
Percentage 75% 25% 100% 
Total  31 69 100 
<0.001 
 
 
Increased number of anti convulsant  drug usage was associated 
with a higher incidence of hypophosphatemia.   
TABLE  -17 
Duration of anticonvulsants and phosphate level 
Duration  Normal po4 
Low po4 Total P value 
Number 6 46 52 >12 
months percentage 11.5% 88.5% 100% 
Number 25 23 48 <12 
months percentage 52.1% 47.9% 100% 
Total  31 69 100 
<0.001 
 
 
Prevalence of hypophosphatemia increases as the duration of drug 
treatment increases.  
 
TABLE  -18 
Correlation of serum phosphorus and vitamin D 
Vitamin 
D 
 Normal 
po4 
Low po4 Total P value 
Number 66 11 77 
Normal 
Percentage 85.7% 14.3% 77.0% 
Number 3 20 23 
Low 
Percentage 13.0% 87.0% 23.0% 
Total  69 31 100.0% 
<0.001 
 
 
Hypophosphatemia was significantly associated with low serum 
levels of vitamin D.  
TABLE  - 19 
Correlation of serum phosphorus and PTH 
PTH 
Level  NormalPO4 Low PO4 Total P value 
Number 68 16 84 Normal 
Percentage 81.0% 19.0% 84.0% 
Number 1 15 16 High 
Percentage 6.3% 93.8% 16.0% 
Total  69 31 100 
<0.001 
 
 
Most patients with hypophosphatemia had elevated parathormone 
levels 
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 DISCUSSION 
 The aim of the thesis was to study the prevalence of hypocalcemia 
among patients on chronic anti convulsant therapy  
(>6  months).  
100 epilepsy patients attending the GGH, Chennai and fulfilling 
the criteria as mentioned in methodology were the subjects of this study. 
The prevalence of hypocalcemia among our study population was 32%.  
In a study done previously by Schmitt BP et al on 56 patients taking 
chronic anti convulsants, 29% (16 patients) were found to have 
hypocalcemia.(68) 
         The correlation between the number of anti convulsant drugs 
the patient taking and the presence of hypocalcemia was statistically 
analyzed. Among the patients on single drug therapy, the prevalence was 
28.1%. Patients taking two drugs had a prevalence of 53.1% and for those 
on three drugs the value was 75%. Hence the number of anti convulsant 
drug usage correlated directly with the chance for hypocalcemia and the 
differences were statistically very significant (p < 0.001). 
The duration of anti convulsant usage and whether that had a 
significant effect on the prevalence of hypocalcemia was analyzed. Those 
taking drugs less than 12 months had a prevalence of 11.5%, while, of the 
patients taking drugs for more than 12 months, 81.3% had hypocalcemia. 
The difference when analysed statistically, was significant, with a p value 
< 0.001. 
         The serum levels of vitamin D was measured in all these 
patients and we found that, out of the 32 patients with hypocalcemia, 30 
(91.3%) also had low levels of vitamin D.  But in the normocalcemic 
group hypovitaminemia D was present only in 14.3% with the difference 
in prevalence being statistically significant (P< 0.001). In a similar study 
done on 56 patients taking chronic anti convulsants, Theodore J. Hahn et 
al reported that the serum calcium concentration of  the patients 
correlated with serum vitamin D levels.(69) 
Next the presence of low vitamin D levels in hypocalcemic patients 
was studied, and it was found that among the 23 patients of hypo 
vitaminosis D, 21 (91.3%) patients also had hypocalcemia and the finding 
was statistically significant. 
The relationship between control of seizures and the presence of 
hypocalcemia was studied. It was found that, in patients with 
hypocalcemia, seizures control was poor, than in those with 
normocalcemia, with a P value of the difference being < 0.001. A similar 
finding was reported in the study done by Ali FE et al.(51)  But of course, 
sub therapeutic levels of anti-convulsants must have been ruled out, 
which, not being done, was one of the limitations of our study. 
In this study, in addition to calcium levels, we also studied the 
correlation of serum Alkaline phosphatase levels with anti convulsant 
drug usage.  Elevated Alkaline phosphatase levels was found in 25 of the 
100 patients studied. Of these patients 19 also had hypocalcemia (76%) 
while the remaining 6 (24%) had isolated elevation of Alkaline 
phosphatase. In the study done by Schmitt BP et al, quoted previously, a 
similar finding was reported, with elevated ALP levels in 27% of the 
study group.(68) 
The elevated Alkaline phosphatase levels were analyzed with 
respect to the duration of drug usage. With single drug use, the 
prevalence was 15.4% while with two and three drugs usage, the 
prevalences were 37% and 62.5% respectively. Thus more the number of 
drugs used, more the chances of elevated Alkaline phosphatase levels. 
Also the effect of duration of therapy on alkaline phosphatase levels was 
considered. Patients on drugs for less than 12 months had a prevalence of 
15.4% while those taking drugs for more than 12 months had a greater 
prevalence of 35.4%. All the above mentioned findings were significant 
on statistical analysis ( p< 0.001).         
The coincidence of occurence of hypocalcemia and elevated ALP 
were analyzed. Of the 32 patients with hypocalcemia, 19(59.3%) also had 
elevated ALP. Isolated elevation of ALP alone was found in 6 (8.8%) 
patients. 
The prevalence of elevated parathyroid hormone in patients with 
hypocalcemia was analyzed and was found to be present in half such 
patients, with statistical significance. 
Also the correlation between low vitamin D and  PTH levels was 
analysed and it was found that, of the 23 patients with low vitamin D,14 
had elevated PTH levels, the number being significant on analysis with p 
value being <0.01. 
Serum phosphate levels were done for the patients and it was found 
that hypophosphatemia was associated with either more number of, or 
longer duration of anti convulsant treatment and also with 
hypovitaminosis D and elevated parathormone levels. The associations 
were found to be statistically significant with p <0.001. 
 
 
 
 
LIMITATIONS 
1. The study was done on patients taking traditional anti convulsants. 
Hence the effect of newer drugs are not studied. 
2. Only the total serum calcium was measured and not the ionised 
calcium which is the metabolically active component. 
3. The serum levels of anti convulsants were not measured in patients, 
so as to attribute hypocalcemia, as the sole cause of poor seizure 
control. 
4. The disease pathology causing seizures and its effect on seizure 
control were not analyzed. 
5. While measuring alkaline phosphatase levels, only the total and not 
the bone iso-enzyme levels were measured. 
6. Calcium and vitamin D supplementation and their effect on seizure 
control was not studied. 
  
 
 
CONCLUSION 
 CONCLUSION 
1. There is a significant prevalence of hypocalcemia in patients on 
chronic anticonvulsant therapy. 
2. The number of anti convulsants used, as well as the duration of 
usage have a significant correlation with the prevalence of 
hypocalcemia. 
3. Hypocalcemia in patients has a significant association with poor 
seizure control even with good drug compliance, when compared 
with normocalcemic patients. 
4. Elevated Alkaline phosphatase levels were found in patients on 
chronic anti convulsant therapy either in isolation or in 
combination with hypocalcemia. 
5. Elevated Alkaline phosphatase levels correlated significantly with 
the duration and number of anti convulsant drug usage. 
6. Hence this study concludes that there is significant hypocalcemia 
and hypovitaminemia D in patients on chronic anti convulsant 
therapy and we suggest that calcium and vitamin D 
supplementation may be beneficial. 
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ANNEXURE 
  
PROFORMO 
Calcium homeostasis abnormalities in chronic anticonvulsant 
therapy 
 
Name     :  
Age      :  
Sex     : 
Hospital number   : 
Drugs used and duration  :  1. 
2. 
3. 
 
Indication for anticonvulsive therapy : 
Other risk factors for bone disease : 
Compliance & Seizure control  :  
History of bone fractures             : 
Clinical examination   : 
Height:                   weight:                   BMI: 
 
Investigations 
Complete Hemogram  
Liver function tests  
Renal function tests  
Serum Vit D2  
Urine Routine  
Serum Calcium  
Serum Phosphorus  
Serum Alkaline phosphatase  
 
 
PATIENT CONSENT FORM 
 
Title  
Calcium homeostasis abnormalities in chronic antiepileptic therapy. 
 
Study centre                : Govt.General hospital, MMC, Chennai 
Patient’s name : 
Patient’s age  : 
Identification number : 
  
 I confirm that I have understood the purpose of the procedures of   the above 
study. I have had the opportunity to ask questions and all my questions have been 
answered satisfactorily. 
 
           I understand that my participation in the study is entirely voluntary and that I 
am free to withdraw from the study at any time without my legal rights being affected            
 
 I understand that sponsors of the study, others working on sponsor’s behalf, 
the ethics committee and the regulatory authorities will not need my permission 
to look at my health records both in respect of current study and any future research 
that may be conducted in relation to it; even if I withdraw from the study I agree to 
this access. However I understand that my identity will not be revealed in any 
information released to third parties unless required by law. I agree not to restrict the 
use of any data or results arising from the study. 
 
 I agree to take part in the above the study an to comply with the instructions 
given during the study and inform about any change in my health status to the 
investigator. 
 
I hereby give permission to undergo complete clinical examination 
and investigations as part of the study. 
 
Signature of the patient       
 
Patient’s name and address   place   date 
 
Signature of the investigator       
 
Investigator’s name    place    date 
 
 
 
 
MASTER CHART 
 
S.
N
o
.
 
A
G
E
 
SE
X
 
D
IA
G
N
O
SI
S 
D
R
U
G
S 
D
U
R
A
TI
O
N
 
C
A
LC
IU
M
-
C
 
PH
O
SP
H
O
R
U
S 
A
LP
 
V
IT
 
D
 
PT
H
 
A
LB
U
M
IN
 
SE
IZ
U
R
E 
C
O
N
TR
O
L 
1. 15 F M P 8 M 10.2 2.8 48 40.4 60 4.2 Y 
2. 40 F PSS P 14 M 7.8 2.3 262 9.4 108.3 3.8 N 
3. 18 F N P 12 M 10.8 3.2 46 56.6 28.6 4 Y 
4. 59 M MR P 9 M 9.4 4 68 37.2 32.5 4.2 Y 
5. 19 M TBM P 14 M 8.2 2.2 288 30.6 20.4 3.8 Y 
6. 32 M CPS C 12 M 9 4 48 14.8 44.6 3.6 Y 
7. 37 F M P+PB+S 12 M 7.6 2.4 202 8.8 382.4 3.8 Y 
8. 27 F M P+S 20 M 7.8 2.2 252 8.6 180.4 4 Y 
9. 40 F PSS P+S 11 M 9.4 3.1 62 18.4 42.4 3.8 Y 
10. 38 M PTS P 12 M 10.6 3.6 42 26.4 45.4 3.6 Y 
11. 25 M MR P 10 M 9.8 3.4 46 34 20.6 3.8 Y 
12. 12 F TBM P+S 7 M 7.8 2.1 212 9.6 121.6 4.2 N 
13. 24 M A S 9 M 10.4 4 54 24 18.6 3.6 Y 
14. 20 M I P 8 M 8.8 4.2 38 16.8 24.8 3.6 Y 
15. 17 F CPS C 24 M 8 2.4 158 9.6 134.6 4 Y 
16. 19 M M P 15 M 9 3.2 246 32.5 40.6 4 Y 
17. 32 F I S 20 M 8.2 2.2 78 19.6 43 3.6 Y 
18. 18 F N S 11 M 9.8 3.8 108 32 28.2 3.8 Y 
19. 29 M I P+PB 9 M 7.8 2 192 8.6 232.4 3.6 Y 
20. 19 F I P 13 M 7.6 2.4 282 8.4 168.4 4.4 Y 
21. 17 F I S 10 M 10.6 3.6 122 20 38.5 4 Y 
22. 20 M CPS C 7 M 10.6 3.4 68 18.4 54 4.2 Y 
23. 39 M PSS P+S 22 M 8.2 2 88 20.2 108.6 3.8 Y 
24. 28 M I P 10 M 10.4 3.6 48 10.8 38.4 4 Y 
25. 17 M N P+C+S 16 M 8.4 2.1 128 10.8 44.2 4.2 Y 
26. 22 F I S 11M 10.2 4 56 35.6 28.6 4.2 Y 
27. 16 F CPS C+S+P 6 M 9.6 4.2 78 30 42.4 4 Y 
28. 40 M TBM P+S 12 M 7.8 2.2 156 9.6 142.4 4.4 N 
29. 33 M I S 10 M 9.4 3.6 40 26.6 20.6 3.8 Y 
30. 31 F N C 12 M 10.2 3.2 196 30.6 42.5 4 Y 
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31. 17 M MR P 7 M 8.4 2.4 224 28.6 46 4 N 
32. 16 M MR P 9 M 9.8 3.6 84 20.4 34.6 4.2 Y 
33. 20 M I P+PB+S 16M 7.6 2.4 320 9.8 126.2 4 Y 
34. 31 M M C+S 17 M 8.2 2 68 40.4 28.6 4.4 Y 
35. 37 M N P 12 M 9.2 4.1 108 38.2 34.6 3.8 Y 
36. 28 M CPS C 10 M 9.8 3.6 44 28 42 4 Y 
37. 30 F I C 18 M 10.4 4.2 48 44 36.5 3.8 Y 
38. 27 M I P+S 16 M 8 3.4 188 8.4 88 4.2 Y 
39. 36 M I P 16 M 10.2 2.6 56 36.6 38.6 4 Y 
40. 41 M I P 24 M 7.8 2.3 286 24 42.6 4 Y 
41. 30 M T S 7 M 10.8 4 48 42 34.6 4 N 
42. 22 M CPS C 19 M 10.4 3.4 96 24.6 36 4.1 Y 
43. 39 F M P+S 14 M 8.2 2.3 56 9.4 46 4 Y 
44. 16 F CPS C 8 M 9.6 3.6 240 20.6 42.4 4.2 Y 
45. 17 M I P 10 M 9 3.2 64 30.8 32.6 4 Y 
46. 22 M TBM S+C 11 M 8 2.4 56 31.8 36 3.6 Y 
47. 29 F I P 12 M 9.4 2.8 88 28.6 34.5 3.8 Y 
48. 16 F I S 14 M 9.6 3.2 80 30.8 34.6 4.4 Y 
49. 28 M M P+B 13 M 8.2 2.4 64 9.6 64 4 Y 
50. 20 M A P 17 M 10.2 2.8 134 40.6 42 4.2 Y 
51. 38 F M P+B 14 M 10.4 3.2 256 37.5 28.4 4 Y 
52. 22 M A P+S 17 M 8 2 204 8.8 242.2 4.2 Y 
53. 46 M PSS P+S 18 M 7.8 2.4 288 9.6 134.2 4 N 
54. 22 F A S 7 M 10.4 4.2 60 23.6 40.4 3.8 Y 
55. 39 F I P 9 M 10.4 4.2 78 31.5 24 3.6 Y 
56. 31 F I P 16 M 8.4 2.3 84 34.4 26 4.4 N 
57. 39 F I S 11 M 9.6 3.2 44 26.6 38.6 4.2 N 
58. 15 F PSS S 9 M 9.2 3.8 46 34.6 24 4.2 Y 
59. 18 F I P+PB+S 18 M 8.2 2.4 96 8.4 86.4 4 N 
60. 35 F N P+S 23 M 8.2 2 196 9.4 66.4 3.8 Y 
61. 38 F I P+S 11 M 9.6 4 202 37.8 38.6 3.8 N 
62. 45 M I P 6 M 10.4 4.2 86 23.8 40.4 3.6 N 
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63. 27 M I P 8 M 10.2 4.2 80 44 36.4 3.6 Y 
64. 29 M M P 19 M 8 2.1 188 32.4 38 4.4 N 
65. 18 F MR S 10 M 9.6 3.6 62 40 45.4 4.2 Y 
66. 32 F M P+PB 9 M 9.2 3.4 42 33.6 32.6 4.2 N 
67. 17 F N P+PB 13 M 8 2 208 9.2 56.4 4 N 
68. 29 M A P 8 M 10.4 3.8 88 43.5 48.4 4 Y 
69. 25 M I C 7 M 10.8 3.6 76 26.4 36 3.6 Y 
70. 14 F I S 18 M 9.6 4.4 54 29.4 42 3.8 Y 
71. 43 M TBM S 18 M 10.4 4.2 64 38.6 46.4 3.8 Y 
72. 33 M M P+S 23 M 8.2 2.4 98 9.4 304.2 4.4 Y 
73. 20 F A S 11 M 8.8 4 112 28.4 42.4 4.2 Y 
74. 31 M TBM P+S+PB 18 M 10.2 3.8 36 34.6 42 4 N 
75. 38 M M P+S 24 M 8.2 2 124 9.6 46.8 4 N 
76. 42 M TBM P 13 M 9.8 3.4 48 42.8 45.6 3.6 Y 
77. 56 F M P 20 M 9.4 3.2 130 38 40.6 4.2 Y 
78. 54 M PSS P 7 M 10.4 3.6 64 28.4 42.6 4.2 Y 
79. 20 F N S 13 M 9.2 4 84 42 38 4.2 Y 
80. 38 F M P+S 18 M 9.6 4.2 44 32.6 26.8 4 Y 
81. 18 F I P+PB+S 24 M 7.8 2.4 246 9.8 238.2 3.8 N 
82. 38 M I P 10 M 10.2 4.2 46 38.6 42 3.6 Y 
83. 32 M I S 14 M 10.8 3.8 56 18.4 42.6 3.6 Y 
84. 30 F I P+S 10 M 9.4 3.4 66 16.8 45.6 4 Y 
85. 24 F A P+S 13 M 10.8 3.2 56 33.6 44.2 4 Y 
86. 24 F A S 19 M 8.8 3.7 42 28.6 48 4.2 N 
87. 35 F M P+PB+S 17 M 8.1 2 224 32.4 33.6 4.2 N 
88. 15 F MR S 11 M 9.4 2.8 68 26.4 40.2 4 Y 
89. 19 F PTS P 10 M 9.8 3.8 52 44 38.4 3.6 Y 
90. 37 F EDH P+S+PB 8 M 10.4 3.4 212 28 38 3.8 Y 
91. 32 M N P 13 M 9.6 4.2 80 32.6 48.4 4.2 Y 
92. 22 F T P+S 20 M 10.6 4.3 46 40.2 56.4 4 Y 
93. 39 F I P 15 M 8.8 4.2 74 37.4 46.4 4.4 Y 
94. 45 M M P+S 6 M 10.4 3.6 80 16 42.2 3.8 Y 
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95. 38 M TBM P 11 M 9.2 3.4 46 28.6 40.4 3.6 Y 
96. 27 F I S 12 M 9.6 3.4 246 34.6 44 3.6 Y 
97. 29 F I P 8 M 10.2 4.2 44 44 28.4 4.2 Y 
98. 26 M I P+S 22 M 8.2 2.3 124 54 24 3.8 N 
99. 31 M M P 10 M 10.8 3.4 56 28.6 42.4 4.4 Y 
100. 42 F I P 11 M 10.4 3.4 60 24.6 48.2 4.2 Y 
 
 
 
 
 
 

